Description
Teduglutide · CAS 197922-42-2 · C164H252N44O55S. UNII 7M19191IKG.
Identification
| CAS Registry Number | 197922-42-2 |
|---|
| PubChem CID | 16139605 |
|---|
| Molecular formula | C164H252N44O55S |
|---|
| UNII (FDA) | 7M19191IKG |
|---|
Computed Descriptors
| Molecular Weight | 3752.1 |
|---|
| XLogP3 | -15.2 |
|---|
| Hydrogen Bond Donor Count | 55 |
|---|
| Hydrogen Bond Acceptor Count | 60 |
|---|
| Rotatable Bond Count | 126 |
|---|
| Exact Mass | 3750.8028943 |
|---|
| Monoisotopic Mass | 3749.7995395 |
|---|
| Topological Polar Surface Area | 1650 |
|---|
| Heavy Atom Count | 264 |
|---|
| Formal Charge | 0 |
|---|
Physical description & handling notes
- 33 amino acid glucagon-like peptide-2 ... analog manufactured using a strain of Escherichia coli modified by recombinant DNA technology
- An enhancement of gastrointestinal fluid absorption (750-1000 mL/day) was observed following daily administrations of teduglutide. An increase in villus height and crypt depth of the intestinal mucosa was also noted. A decrease in fecal weight has also been observed. Teduglutide does not prolong the QTc interval.
- Subcutaneous injection: Powder for solution / 5mg/vial, Revestive
- Parenteral: For injection, for subcutaneous use, 5 mg (delivers 3.8 mg/0.38 mL) Gattex (available as a kit with sterile water for injection diluent, needles, syringes, and alcohol swabs), NPS Pharmaceuticals
Documented Uses
- Preparation: D.J. Drucker et al., World Intellectual Property Organization patent 9739031; edim, United States of America patent 5789379 (1997, 1998 both to Allelix).
- 33 amino acid glucagon-like peptide-2 ... analog manufactured using a strain of Escherichia coli modified by recombinant DNA technology
- Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
- Breast Feeding; Lactation; Milk, Human; Incretins; Glucagon-Like Peptide-1 Agonists; GLP-1 Agonists
- Gattex (teduglutide [rDNA origin]) for injection is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. /Included in US product label/
- Teduglutide may increase intestinal absorption of drugs and should be used with caution in patients receiving concomitant oral therapy with CNS agents (e.g., benzodiazepines, antipsychotic agents), drugs that require dosage titration, or drugs that have a narrow therapeutic index.
Synonyms
Teduglutide; Gattex; 197922-42-2; revestive; ALX-0600; Gattex Kit; Gly(2)-GLP-2; ALX 0600; Glucagon-like peptide II (2-glycine) (human); CHEBI:72305; 7M19191IKG; teduglutidum; RefChem:56099; A16AX08; DTXSID501027767; Glucagon-like Peptide II (2-glycine)
Frequently Asked Questions
What are the CAS number and molecular formula of Teduglutide?
CAS 197922-42-2; molecular formula C164H252N44O55S; molecular weight — g/mol.
What other names is Teduglutide known by?
Teduglutide, Gattex, 197922-42-2, revestive, ALX-0600, Gattex Kit.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.
